STRUCTURAL REQUIREMENTS FOR INTERACTION OF PTH WITH ITS RECEPTOR
PTH 与其受体相互作用的结构要求
基本信息
- 批准号:6270395
- 负责人:
- 金额:$ 9.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-08-01 至 1998-11-30
- 项目状态:已结题
- 来源:
- 关键词:calcium chimeric proteins conformation crosslink cyanogen bromide cyclic AMP gene mutation hormone receptor nuclear magnetic resonance spectroscopy nucleic acid sequence parathyroid hormone related protein phospholipase C photoactivation protein kinase A protein structure function receptor binding site directed mutagenesis tissue /cell culture
项目摘要
The vital role of parathyroid hormone (PTH) in regulating serum calcium
levels, and the involvement of PTH-related peptide (PTHrP) in embryonic
development as well as its identification as the causative agent of
severe hypercalcemia associated with certain malignancies, underscore the
need for a thorough understanding of how these peptides bind to and
activate their receptor. The primary goals of the experiments proposed
here are 1) to identify critical residues in the ligand and to determine
how they contribute to conformation, receptor binding and receptor
activation, and 2) to identify and characterize key residues in the
receptor with which the ligand interacts. It is expected that many
residues in PTH contribute to the complex array of receptor-ligand
interactions. We shall initially focus on those residues in PTH which
our scanning mutagenesis studies show to be important. We have developed
methods utilizing cells transfected with cloned PTH receptors and short
synthetic PTH analogs to distinguish whether critical binding residues
are involved in long-range intramolecular interactions or shorter-range
interactions, e.g. with nearby residues on the receptor. Mutations which
disrupt long-range interactions are to be used to isolate intragenic,
second-site suppressor mutations that correct the binding defect of the
primary site mutation. Such pairs of mutations will genetically identify
two interacting sites in the ligand. In similar studies involving
PTH/PTHrP hybrid peptides and a collaboration with Dr. M. Weiss, we shall
correlate alterations in function with alterations in structure using the
methods of 2D NMR. the collection of PTH analogs generated in aim I will
be screened for receptor-specific effects using structurally distinct
receptors generated by site-directed mutagenesis or derived from the
cloning experiments described in Dr. Juppner's proposal (Subproject I).
We shall map the sites in the receptor which determine the observed
specificity using chimeric receptors and subsequent point mutation
analysis as we have done for [Arg2]-PTH. Key receptor sites will be
evaluated by saturation mutagenesis and the resulting mutants will be
screened for ligand-specific effects and for activation-constitutive and
activation-defective phenotypes. the large ligand-binding region of the
receptor, which has been roughly mapped to between residues 1 and 300,
will be systematically dissected using a series of deletions, followed
by localized random mutagenesis and finally point mutation analysis. to
complement these genetic approaches, we shall obtain direct evidence of
specific ligand-receptor interactions by physically cross-linking a
series of photoderivatized ligands to the receptor. The cross-linked
sites will be characterized by fragmenting the complex with CNBr and
sequencing the SDS-gel-purified label fragment. These studies should
provide a substantial amount of new information about how PTH and PTHrP
bind to and activate their common receptor. The data should thus lay the
groundwork for the rational design of novel analogs which can be used to
pharmacologically control the complex biologic effects of these potent
peptides.
甲状旁腺素对血钙的调节作用
水平,以及胚胎中PTH相关肽(PTHrP)的参与
发展及其作为病原体的鉴定
严重高钙血症与某些恶性肿瘤,强调
需要彻底了解这些肽如何结合,
激活它们的受体。 提出的实验的主要目标
这里有1)识别配体中的关键残基并确定
它们如何影响构象、受体结合和受体
活化,和2)鉴定和表征在所述细胞中的关键残基。
与配体相互作用的受体。 预计许多
PTH中的残基有助于受体-配体的复杂阵列
交互. 我们将首先关注PTH中的那些残留物,
我们的扫描诱变研究显示是重要的。 我们已经开发
方法利用用克隆的PTH受体和短
合成PTH类似物,以区分关键结合残基
参与长程分子内相互作用或短程
在一些实施方案中,所述化合物可以与例如与受体上的邻近残基的相互作用结合。 的突变
破坏长距离相互作用将用于分离基因内,
第二位点抑制突变,其纠正了
一级位点突变 这种成对的突变将从基因上识别
两个相互作用的位点 在类似的研究中,
PTH/PTHrP杂合肽以及与M.韦斯,我们
将功能改变与结构改变相关联,
2D NMR方法。 在目的I中产生的PTH类似物的集合将
使用结构上不同的
通过定点诱变产生的或衍生自
克隆实验在Dr. Bennpner的建议中描述(子项目I)。
我们将绘制受体中决定所观察到的
使用嵌合受体和随后的点突变的特异性
我们对[Arg 2]-PTH进行了分析。 关键受体位点将是
通过饱和诱变进行评价,将得到的突变体
筛选配体特异性效应和活化组成性,
活化缺陷表型。 大的配体结合区,
受体,已大致定位于残基1和300之间,
将使用一系列删除进行系统解剖,然后
通过局部随机诱变和最后的点突变分析。 到
补充这些遗传学方法,我们将获得直接的证据,
特异性配体-受体相互作用通过物理交联
一系列的光衍生配体的受体。 交联
位点将通过用CNBr使复合物片段化来表征,
对SDS-凝胶纯化的标记片段进行测序。 这些研究应
提供了大量关于PTH和PTHrP
结合并激活它们的共同受体。 因此,数据应该奠定
为合理设计新型类似物奠定基础,
控制这些强大的生物效应
缩氨酸
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS J GARDELLA其他文献
THOMAS J GARDELLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS J GARDELLA', 18)}}的其他基金
PTH Inverse Agonists as Therapy for Jansen’s Disease
PTH 反向激动剂治疗詹森病
- 批准号:
9980390 - 财政年份:2018
- 资助金额:
$ 9.36万 - 项目类别:
PTH Inverse Agonists as Therapy for Jansen’s Disease
PTH 反向激动剂治疗詹森病
- 批准号:
10200028 - 财政年份:2018
- 资助金额:
$ 9.36万 - 项目类别:
PTH and PTHrP Interaction with PTH Receptors
PTH 和 PTHrP 与 PTH 受体的相互作用
- 批准号:
7325707 - 财政年份:2006
- 资助金额:
$ 9.36万 - 项目类别:
PTH and PTHrP Interaction with PTH Receptors
PTH 和 PTHrP 与 PTH 受体的相互作用
- 批准号:
7160504 - 财政年份:2005
- 资助金额:
$ 9.36万 - 项目类别:
PTH and PTHrP Interaction with PTH Receptors
PTH 和 PTHrP 与 PTH 受体的相互作用
- 批准号:
7062731 - 财政年份:2004
- 资助金额:
$ 9.36万 - 项目类别:
PTH and PTHrP Interaction with PTH Receptors
PTH 和 PTHrP 与 PTH 受体的相互作用
- 批准号:
6744649 - 财政年份:2003
- 资助金额:
$ 9.36万 - 项目类别:
PTH AND PTHRP INTERACTION WITH PTH RECEPTORS
PTH 和 PTHRP 与 PTH 受体的相互作用
- 批准号:
6564092 - 财政年份:2001
- 资助金额:
$ 9.36万 - 项目类别:
PTH AND PTHRP INTERACTION WITH PTH RECEPTORS
PTH 和 PTHRP 与 PTH 受体的相互作用
- 批准号:
6410290 - 财政年份:2000
- 资助金额:
$ 9.36万 - 项目类别:
PTH AND PTHRP INTERACTION WITH PTH RECEPTORS
PTH 和 PTHRP 与 PTH 受体的相互作用
- 批准号:
6300957 - 财政年份:1999
- 资助金额:
$ 9.36万 - 项目类别:
PTH AND PTHRP INTERACTION WITH PTH RECEPTORS
PTH 和 PTHRP 与 PTH 受体的相互作用
- 批准号:
6104979 - 财政年份:1999
- 资助金额:
$ 9.36万 - 项目类别:
相似海外基金
Non-canonical chimeric proteins generated during Adenovirus infection
腺病毒感染期间产生的非典型嵌合蛋白
- 批准号:
10448505 - 财政年份:2021
- 资助金额:
$ 9.36万 - 项目类别:
Non-canonical chimeric proteins generated during Adenovirus infection
腺病毒感染期间产生的非典型嵌合蛋白
- 批准号:
10312411 - 财政年份:2021
- 资助金额:
$ 9.36万 - 项目类别:
Increasing efficiency in formation of chimeric proteins
提高嵌合蛋白形成的效率
- 批准号:
561998-2021 - 财政年份:2021
- 资助金额:
$ 9.36万 - 项目类别:
University Undergraduate Student Research Awards
Decoration and Dimerization of Chimeric Proteins Mediated by Coiled-Coil Interactions
卷曲螺旋相互作用介导的嵌合蛋白的修饰和二聚化
- 批准号:
537306-2018 - 财政年份:2019
- 资助金额:
$ 9.36万 - 项目类别:
Collaborative Research and Development Grants
Exploring the therapeutic potential of chimeric proteins
探索嵌合蛋白的治疗潜力
- 批准号:
1947736 - 财政年份:2017
- 资助金额:
$ 9.36万 - 项目类别:
Studentship
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS
靶向蛋白质相互作用并设计嵌合蛋白质
- 批准号:
8364271 - 财政年份:2011
- 资助金额:
$ 9.36万 - 项目类别:
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
用于治疗花生过敏的治疗性花生过敏原 Fc γ 嵌合蛋白
- 批准号:
8444422 - 财政年份:2010
- 资助金额:
$ 9.36万 - 项目类别:
Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy
猫过敏原-人Fc-gamma1嵌合蛋白治疗猫过敏
- 批准号:
7907314 - 财政年份:2010
- 资助金额:
$ 9.36万 - 项目类别:
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS
靶向蛋白质相互作用并设计嵌合蛋白质
- 批准号:
8171849 - 财政年份:2010
- 资助金额:
$ 9.36万 - 项目类别:
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
用于治疗花生过敏的治疗性花生过敏原 Fc γ 嵌合蛋白
- 批准号:
8313432 - 财政年份:2010
- 资助金额:
$ 9.36万 - 项目类别: